What this study is
SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. SCOPE specimens will be used to examine multiple questions involving virologic, immunologic, and host factors involved in HIV-1 infection, progression, non-progression, response to treatment, control of HIV-1 virus, and evolution of drug resistance.
Study details
- Sponsor
- University of California, San Francisco
- Conditions
- HIV Infections
- Enrolling
- 2,500 people
- Starts
- 2000-03
- Est. completion
- 2033-12
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Documented HIV viral load less than 2000 copies/ml WITHOUT taking antiretroviral therapy
- Undetectable HIV viral load with CD4 T-cells consistently less than 350 for the last 12 months while taking a stable antiretroviral regimen.
- Antiretroviral naive and planning to start an antiretroviral regimen - any CD4 or HIV viral load acceptable.
- Long-term Non Progressors: HIV-positive at least 10 years, no antiretroviral therapy for the past 10 years or more, any viral load acceptable, CD4-T cell count always above 500.
You can't join if
- Active opportunistic infection or systemic treatment for opportunistic infection within the last 4 months (oral candidiasis acceptable)
- Active treatment for cancer
- Active treatment for hepatitis C requiring interferon based therapy
- Immunosuppressive therapy taken within the last 4 months
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openSan Francisco General Hospital
San Francisco, California, United States
- Rebecca Hoh, M.S. · Contact415-476-4082 ext. 139Rebecca.Hoh@ucsf.edu
- Montha Pao · Contact415-476-4082 ext. 140Montha.Pao@ucsf.edu
- Steven G. Deeks, M.D. · Principal investigator
Recruiting
Study team
Sponsor
University of California, San Francisco
Study ID 10-01330
Principal investigator
Steven G. Deeks, M.D.
University of California, San Francisco
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.